3300 A phase 1b/2 study of ribociclib (LEE011; CDK4/6 inhibitor) in combination with binimetinib (MEK162; MEK inhibitor) in patients with NRAS-mutant melanoma. (September 2015) - Van Herpen, C.; Postow, M.A.; Carlino, M.S.; Kalkavan, H.; Weise, A.; Amaria, R.N.; Vos, F. De; Carvajal, R.D.; Matano, A.; Bhansali, S.; Lam, L.; Yerramilli-Rao, P.; et al.